Zoetis Inc.
Zoetis Inc. Announces Resignation of Executive Vice President and General Counsel Heidi C. Chen
Summary
Zoetis Inc. announced on April 16, 2024, the resignation of Heidi C. Chen, its Executive Vice President, General Counsel, and Corporate Secretary, effective immediately. Chen will serve as an employee advisor until July 16, 2024, after which she is expected to serve as a non-employee consultant. Roxanne Lagano will serve as interim General Counsel while the company searches for a permanent replacement. Chen is eligible for separation benefits under the company's Executive Severance Plan and certain retirement benefits.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement